Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CTIC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.20
N/A
-0.20
vs -0.14
Q1.21
N/A
-0.23
vs -0.20
Q2.21
N/A
-0.21
vs -0.19
Q3.21
N/A
-0.26
vs -0.15
Q4.21
N/A
-0.39
vs -0.20
Q1.22
N/A
-0.37
vs -0.23
Q2.22
N/A
-0.21
vs -0.21
Q3.22
N/A
-0.13
vs -0.26
Q4.22
N/A
-0.14
vs -0.39
Q1.23
N/A
-0.10
vs -0.37
Sales Growth
YoY
Current
Estimates
Q4.20
NA
NA vs NA
Q1.21
NA
NA vs NA
Q2.21
NA
NA vs NA
Q3.21
NA
NA vs NA
Q4.21
NA
NA vs NA
Q1.22
NA
2.3M vs NA
Q2.22
NA
12.3M vs NA
Q3.22
NA
18.2M vs NA
Q4.22
NA
21.1M vs NA
Q1.23
+951%
24.1M vs 2.3M
Return on Equity
QoQ
Q2.21
-32%
-0.32
vs -0.65
Q3.21
-62%
-0.62
vs -0.32
Q4.21
-1014%
-10.14
vs -0.62
Q1.22
+133%
1.33
vs -10.14
Q2.22
+430%
4.3
vs 1.33
Q3.22
+93%
0.93
vs 4.3
Q4.22
+96%
0.96
vs 0.93
Q1.23
+86%
0.86
vs 0.96
Institutionnal Ownership
QoQ
Q3.21
56
56
vs 47
19%
Q4.21
64
64
vs 56
14%
Q1.22
94
94
vs 64
47%
Q2.22
121
121
vs 94
29%
Q3.22
138
138
vs 121
14%
Q4.22
155
155
vs 138
12%
Q1.23
143
143
vs 155
-8%
Q2.23
3
3
vs 143
-98%
prnewswire.com
7 hours ago
prnewswire.com
9 hours ago
prnewswire.com
16 hours ago
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
SVB Leerink
initialisePrevious: Not converted
2022-10-17
Now: Outperform
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.01 ( 0.06%)
Pre-market 0.00$
-9.10 (-100.00%)
Relative Strenght
98
Volume Buzz
-2%
Earning Acce
No
Dist 52w H.
0%Relative Strength
CTIC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
